{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:04:05Z","timestamp":1790381045573,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RTI2018-101034-B-I00"],"award-info":[{"award-number":["RTI2018-101034-B-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PRE2021-098133"],"award-info":[{"award-number":["PRE2021-098133"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n la Caixa","award":["LCF\/BQ\/DI18\/11660018"],"award-info":[{"award-number":["LCF\/BQ\/DI18\/11660018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13346-023-01374-z","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T13:01:53Z","timestamp":1687352513000},"page":"3077-3093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood\u2013brain barrier"],"prefix":"10.1007","volume":"13","author":[{"given":"Maximilian","family":"Loeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Placci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"1374_CR1","unstructured":"OMIM Entry - # 257200 - NIEMANN-PICK DISEASE, TYPE A."},{"key":"1374_CR2","unstructured":"OMIM Entry - # 607616 - NIEMANN-PICK DISEASE, TYPE B."},{"key":"1374_CR3","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/B978-0-444-59565-2.00041-1","volume":"113","author":"MT Vanier","year":"2013","unstructured":"Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717\u201321.","journal-title":"Handb Clin Neurol"},{"key":"1374_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","volume":"30","author":"EH Schuchman","year":"2007","unstructured":"Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis. 2007;30:654\u201363.","journal-title":"J Inherit Metab Dis"},{"key":"1374_CR5","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/j.bbamem.2014.02.021","volume":"1838","author":"PJ Quinn","year":"2014","unstructured":"Quinn PJ. Sphingolipid symmetry governs membrane lipid raft structure. Biochim Biophys Acta. 2014;1838:1922\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"1374_CR6","doi-asserted-by":"crossref","unstructured":"Abe A, Shayman JA. Sphingolipid catabolism. Encycl Biol Chem Second Ed. 2013;287\u2013292.","DOI":"10.1016\/B978-0-12-378630-2.00462-X"},{"key":"1374_CR7","doi-asserted-by":"crossref","unstructured":"Breiden B, Sandhoff K. Acid sphingomyelinase, a lysosomal and secretory phospholipase C, is key for cellular phospholipid catabolism. Int J Mol Sci.\u00a02021;22:9001.","DOI":"10.3390\/ijms22169001"},{"key":"1374_CR8","doi-asserted-by":"crossref","unstructured":"Wasserstein MP, et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114:e672\u20137.","DOI":"10.1542\/peds.2004-0887"},{"key":"1374_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ymgme.2012.06.015","volume":"107","author":"CEM Hollak","year":"2012","unstructured":"Hollak CEM, et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab. 2012;107:526\u201333.","journal-title":"Mol Genet Metab"},{"key":"1374_CR10","doi-asserted-by":"crossref","unstructured":"McGovern MM, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics. 2008;122:e341\u20139.","DOI":"10.1542\/peds.2007-3016"},{"key":"1374_CR11","doi-asserted-by":"crossref","unstructured":"Mar\u00edn T, et al. c-Abl activation linked to autophagy-lysosomal dysfunction contributes to neurological impairment in Niemann-Pick type A disease. Front Cell Dev Biol. 2022;10:844297.","DOI":"10.3389\/fcell.2022.844297"},{"key":"1374_CR12","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s12031-022-02036-4","volume":"72","author":"EV Carsana","year":"2022","unstructured":"Carsana EV, et al. Massive accumulation of sphingomyelin affects the lysosomal and mitochondria compartments and promotes apoptosis in Niemann-Pick disease type A. J Mol Neurosci. 2022;72:1482\u201399.","journal-title":"J Mol Neurosci"},{"key":"1374_CR13","doi-asserted-by":"crossref","unstructured":"Gaband\u00e9\u2010Rodr\u00edguez E, et al. Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders. EMBO J. 2019;38:e99553.","DOI":"10.15252\/embj.201899553"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66:228\u201332.","journal-title":"Neurology"},{"key":"1374_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40265-022-01727-x","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Olipudase Alfa: first approval. Drugs. 2022;82:941\u20137.","journal-title":"Drugs"},{"key":"1374_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0167-4838(99)00069-2","volume":"1432","author":"X He","year":"1999","unstructured":"He X, et al. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim Biophys Acta. 1999;1432:251\u201364.","journal-title":"Biochim Biophys Acta"},{"key":"1374_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2021;23:1543\u201350.","journal-title":"Genet Med"},{"key":"1374_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13346-012-0072-4","volume":"2","author":"S Muro","year":"2012","unstructured":"Muro S. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. Drug Deliv Transl Res. 2012;2:169\u201386.","journal-title":"Drug Deliv Transl Res"},{"key":"1374_CR19","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1096\/fj.00-0014com","volume":"14","author":"SRP Miranda","year":"2000","unstructured":"Miranda SRP, et al. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 2000;14:1988\u201395.","journal-title":"FASEB J"},{"key":"1374_CR20","doi-asserted-by":"crossref","unstructured":"Tomsen-Melero J, et al. Liposomal formulations for treating lysosomal storage disorders. Adv Drug Deliv Rev. 2022;190:114531.","DOI":"10.1016\/j.addr.2022.114531"},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","volume":"118","author":"M Solomon","year":"2017","unstructured":"Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"1374_CR22","doi-asserted-by":"crossref","unstructured":"Del Grosso A, Parlanti G, Mezzena R, Cecchini M. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders. Adv Drug Deliv Rev. 2022;188:114464.","DOI":"10.1016\/j.addr.2022.114464"},{"key":"1374_CR23","doi-asserted-by":"crossref","unstructured":"Seras-Franzoso J, et al. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. J Extracell Vesicles. 2021;10:e12058.","DOI":"10.1002\/jev2.12058"},{"key":"1374_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2017.02.016","volume":"253","author":"T Schuster","year":"2017","unstructured":"Schuster T, et al. Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A. J Control Release. 2017;253:1\u201310.","journal-title":"J Control Release"},{"key":"1374_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11095-014-1508-y","volume":"32","author":"FQ Mayer","year":"2015","unstructured":"Mayer FQ, et al. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res. 2015;32:941\u201354.","journal-title":"Pharm Res"},{"key":"1374_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0156452","volume":"11","author":"M Salvalaio","year":"2016","unstructured":"Salvalaio M, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE. 2016;11:1\u201317.","journal-title":"PLoS ONE"},{"key":"1374_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20082014","volume":"20","author":"L Rigon","year":"2019","unstructured":"Rigon L, et al. Targeting brain disease in MPSII: preclinical evaluation of IDS-loaded PLGA nanoparticles. Int J Mol Sci. 2019;20:1\u201315.","journal-title":"Int J Mol Sci"},{"key":"1374_CR28","doi-asserted-by":"crossref","unstructured":"Del Grosso A, et al. Brain-targeted enzyme-loaded nanoparticles: a breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Sci Adv. 2019;5:eaax7462.","DOI":"10.1126\/sciadv.aax7462"},{"key":"1374_CR29","doi-asserted-by":"crossref","unstructured":"Tian X, et al. LRP-1-mediated intracellular antibody delivery to the central nervous system. Sci Rep. 2015;5:11990.","DOI":"10.1038\/srep11990"},{"key":"1374_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2020.05.009","volume":"324","author":"RL Manthe","year":"2020","unstructured":"Manthe RL, et al. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme. J Control Release. 2020;324:181\u201393.","journal-title":"J Control Release"},{"key":"1374_CR31","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.3390\/ijms23074034","volume":"23","author":"E Muntimadugu","year":"2022","unstructured":"Muntimadugu E, et al. Comparison between nanoparticle encapsulation and surface loading for lysosomal enzyme replacement therapy. Int J Mol Sci. 2022;23:4034.","journal-title":"Int J Mol Sci"},{"key":"1374_CR32","doi-asserted-by":"crossref","unstructured":"Muro S. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. in Endothelial Biomed. (ed. Aird, W.) 2007;1058\u20131070 (Cambridge University Press).","DOI":"10.1017\/CBO9780511546198.118"},{"key":"1374_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1242\/jcs.00367","volume":"116","author":"S Muro","year":"2003","unstructured":"Muro S, et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci. 2003;116:1599\u2013609.","journal-title":"J Cell Sci"},{"key":"1374_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymthe.2005.07.687","volume":"13","author":"S Muro","year":"2006","unstructured":"Muro S, Schuchman EH, Muzykantov VR. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther. 2006;13:135\u201341.","journal-title":"Mol Ther"},{"key":"1374_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/1061186X.2017.1349771","volume":"25","author":"C Garnacho","year":"2017","unstructured":"Garnacho C, Muro S. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement. J Drug Target. 2017;25:786\u201395.","journal-title":"J Drug Target"},{"key":"1374_CR36","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.ymthe.2017.05.014","volume":"25","author":"C Garnacho","year":"2017","unstructured":"Garnacho C, Dhami R, Solomon M, Schuchman EH, Muro S. Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-Pick disease mice. Mol Ther. 2017;25:1686\u201396.","journal-title":"Mol Ther"},{"key":"1374_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10545-012-9534-6","volume":"36","author":"J Papademetriou","year":"2013","unstructured":"Papademetriou J, et al. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J Inherit Metab Dis. 2013;36:467\u201377.","journal-title":"J Inherit Metab Dis"},{"key":"1374_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1124\/jpet.107.133298","volume":"325","author":"C Garnacho","year":"2008","unstructured":"Garnacho C, et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther. 2008;325:400\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1374_CR39","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2008.127","volume":"16","author":"S Muro","year":"2008","unstructured":"Muro S, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther. 2008;16:1450\u20138.","journal-title":"Mol Ther"},{"key":"1374_CR40","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1016\/j.biomaterials.2013.01.069","volume":"34","author":"IT Papademetriou","year":"2013","unstructured":"Papademetriou IT, Garnacho C, Schuchman EH, Muro S. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials. 2013;34:3459\u201366.","journal-title":"Biomaterials"},{"key":"1374_CR41","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s11095-013-1289-8","volume":"31","author":"J Hsu","year":"2014","unstructured":"Hsu J, Rappaport J, Muro S. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier. Pharm Res. 2014;31:1855\u201366.","journal-title":"Pharm Res"},{"key":"1374_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2019.03.008","volume":"301","author":"OA Marcos-Contreras","year":"2019","unstructured":"Marcos-Contreras OA, et al. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J Control Release. 2019;301:54\u201361.","journal-title":"J Control Release"},{"key":"1374_CR43","doi-asserted-by":"crossref","unstructured":"Glassman PM, et al. Targeted nanocarriers coopting pulmonary leukocytes for drug delivery to the injured brain. bioRxiv. 2022;479150.","DOI":"10.1101\/2022.02.04.479150"},{"key":"1374_CR44","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1471-4159.2007.04976.x","volume":"103","author":"T Moos","year":"2007","unstructured":"Moos T, Nielsen TR, Skj\u00f8rringe T, Morgan EH. Iron trafficking inside the brain. J Neurochem. 2007;103:1730\u201340.","journal-title":"J Neurochem"},{"key":"1374_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","volume":"12","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Blood\u2013brain barrier delivery. Drug Discov Today. 2007;12:54\u201361.","journal-title":"Drug Discov Today"},{"key":"1374_CR46","doi-asserted-by":"crossref","unstructured":"Pardridge WM. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. Adv Drug Deliv Rev. 2022;184:114234.","DOI":"10.1016\/j.addr.2022.114234"},{"key":"1374_CR47","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jcb.20596","volume":"96","author":"L Wu","year":"2005","unstructured":"Wu L, Gonias SL. The low-density lipoprotein receptor-related protein-1 associates transiently with lipid rafts. J Cell Biochem. 2005;96:1021\u201333.","journal-title":"J Cell Biochem"},{"key":"1374_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/BJ20061736","volume":"402","author":"DR Taylor","year":"2007","unstructured":"Taylor DR, Hooper NM. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J. 2007;402:17\u201323.","journal-title":"Biochem J"},{"key":"1374_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0169-409X(01)00141-7","volume":"49","author":"JE Schnitzer","year":"2001","unstructured":"Schnitzer JE. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Deliv Rev. 2001;49:265\u201380.","journal-title":"Adv Drug Deliv Rev"},{"key":"1374_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/nnm.11.11","volume":"6","author":"G Tosi","year":"2011","unstructured":"Tosi G, et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond). 2011;6:423\u201336.","journal-title":"Nanomedicine (Lond)"},{"key":"1374_CR51","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.devcel.2012.11.003","volume":"23","author":"RV Stan","year":"2012","unstructured":"Stan RV, et al. The diaphragms of fenestrated endothelia\u2014gatekeepers of vascular permeability and blood composition. Dev Cell. 2012;23:1203.","journal-title":"Dev Cell"},{"key":"1374_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2017.12.025","volume":"272","author":"VV Shuvaev","year":"2018","unstructured":"Shuvaev VV, et al. Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin. J Control Release. 2018;272:1\u20138.","journal-title":"J Control Release"},{"key":"1374_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab. 2017;120:27.","journal-title":"Mol Genet Metab"},{"key":"1374_CR54","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/cdd.2014.4","volume":"21","author":"E Gaband\u00e9-Rodr\u00edguez","year":"2014","unstructured":"Gaband\u00e9-Rodr\u00edguez E, Boya P, Labrador V, Dotti CG, Ledesma MD. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ. 2014;21:864\u201375.","journal-title":"Cell Death Differ"},{"key":"1374_CR55","doi-asserted-by":"crossref","unstructured":"Breiden B, Sandhoff K. Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease. Int J Mol Sci.\u00a02020;21.","DOI":"10.3390\/ijms21072566"},{"key":"1374_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100780","volume":"28","author":"MS Breilyn","year":"2021","unstructured":"Breilyn MS, Zhang W, Yu C, Wasserstein MP. Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency. Mol Genet Metab Reports. 2021;28: 100780.","journal-title":"Mol Genet Metab Reports"},{"key":"1374_CR57","doi-asserted-by":"crossref","unstructured":"Van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008;92:9, 112\u2013124.","DOI":"10.1038\/nrm2330"},{"key":"1374_CR58","doi-asserted-by":"crossref","unstructured":"Stieger B, Steiger J, Locher KP. Membrane lipids and transporter function. Biochim Biophys Acta - Mol Basis Dis.\u00a02021;1867, 166079.","DOI":"10.1016\/j.bbadis.2021.166079"},{"key":"1374_CR59","doi-asserted-by":"crossref","unstructured":"Casares D, Escrib\u00e1 PV, Rossell\u00f3 CA. Membrane Lipid composition: effect on membrane and organelle structure, function and compartmentalization and therapeutic avenues. Int J Mol Sci. 2019;20:2167.","DOI":"10.3390\/ijms20092167"},{"key":"1374_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0962-8924(00)01847-X","volume":"10","author":"K Simons","year":"2000","unstructured":"Simons K, Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol. 2000;10:459\u201362.","journal-title":"Trends Cell Biol"},{"key":"1374_CR61","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1038\/emboj.2010.237","volume":"29","author":"A Fraldi","year":"2010","unstructured":"Fraldi A, et al. Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders. EMBO J. 2010;29:3607.","journal-title":"EMBO J"},{"key":"1374_CR62","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1021\/mp500241y","volume":"11","author":"J Rappaport","year":"2014","unstructured":"Rappaport J, Garnacho C, Muro S. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Mol Pharm. 2014;11:2887\u201395.","journal-title":"Mol Pharm"},{"key":"1374_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1021\/acs.molpharmaceut.5b00542","volume":"13","author":"J Rappaport","year":"2016","unstructured":"Rappaport J, Manthe RL, Solomon M, Garnacho C, Muro S. A comparative study on the alterations of endocytic pathways in multiple lysosomal storage disorders. Mol Pharm. 2016;13:357\u201368.","journal-title":"Mol Pharm"},{"key":"1374_CR64","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1074\/jbc.M309465200","volume":"279","author":"R Dhami","year":"2004","unstructured":"Dhami R, Schuchman EH. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem. 2004;279:1526\u201332.","journal-title":"J Biol Chem"},{"key":"1374_CR65","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1021\/mp5005959","volume":"12","author":"J Rappaport","year":"2015","unstructured":"Rappaport J, Manthe RL, Garnacho C, Muro S. Altered clathrin-independent endocytosis in type A Niemann-Pick disease cells and rescue by ICAM-1-targeted enzyme delivery. Mol Pharm. 2015;12:1366\u201376.","journal-title":"Mol Pharm"},{"key":"1374_CR66","doi-asserted-by":"crossref","unstructured":"Roki N, et al. A method to improve quantitative radiotracing\u2010based analysis of the in vivo biodistribution of drug carriers. Bioeng Transl Med. 2021;6:e10208.","DOI":"10.1002\/btm2.10208"},{"key":"1374_CR67","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1021\/la203095p","volume":"28","author":"ME Wiseman","year":"2012","unstructured":"Wiseman ME, Frank CW. Antibody adsorption and orientation on hydrophobic surfaces. Langmuir. 2012;28:1765\u201374.","journal-title":"Langmuir"},{"key":"1374_CR68","doi-asserted-by":"crossref","unstructured":"Beckmann N, Sharma D, Gulbins E, Becker KA, Edelmann B. Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Front Physiol. 2014;5:331.","DOI":"10.3389\/fphys.2014.00331"},{"key":"1374_CR69","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jconrel.2022.07.022","volume":"349","author":"M Solomon","year":"2022","unstructured":"Solomon M, et al. Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases. J Control Release. 2022;349:1031\u201344.","journal-title":"J Control Release"},{"key":"1374_CR70","first-page":"21","volume":"283","author":"S Muro","year":"2004","unstructured":"Muro S, Muzykantov VR, Murciano JC. Characterization of endothelial internalization and targeting of antibody-enzyme conjugates in cell cultures and in laboratory animals. Methods Mol Biol. 2004;283:21\u201336.","journal-title":"Methods Mol Biol"},{"key":"1374_CR71","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","volume":"108","author":"TM Bui","year":"2020","unstructured":"Bui TM, Wiesolek HL, Sumagin R. ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108:787\u201399.","journal-title":"J Leukoc Biol"},{"key":"1374_CR72","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1124\/jpet.105.098970","volume":"317","author":"S Muro","year":"2006","unstructured":"Muro S, et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther. 2006;317:1161\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"1374_CR73","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.febslet.2009.11.083","volume":"584","author":"EH Schuchman","year":"2010","unstructured":"Schuchman EH. Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. FEBS Lett. 2010;584:1895\u2013900.","journal-title":"FEBS Lett"},{"key":"1374_CR74","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.nano.2016.12.019","volume":"13","author":"JS Brenner","year":"2017","unstructured":"Brenner JS, et al. Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine. 2017;13:1495\u2013506.","journal-title":"Nanomedicine"},{"key":"1374_CR75","doi-asserted-by":"publisher","first-page":"1802373","DOI":"10.1002\/adma.201802373","volume":"30","author":"JW Myerson","year":"2018","unstructured":"Myerson JW, et al. Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles. Adv Mater. 2018;30:1802373.","journal-title":"Adv Mater"},{"key":"1374_CR76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.addr.2015.10.011","volume":"99","author":"JW Myerson","year":"2016","unstructured":"Myerson JW, et al. Non-affinity factors modulating vascular targeting of nano- and microcarriers. Adv Drug Deliv Rev. 2016;99:97\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"key":"1374_CR77","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s11095-014-1531-z","volume":"32","author":"J Hsu","year":"2015","unstructured":"Hsu J, Hoenicka J, Muro S. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Pharm Res. 2015;32:1264\u201378.","journal-title":"Pharm Res"},{"key":"1374_CR78","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/ATVBAHA.111.244186","volume":"32","author":"D Serrano","year":"2012","unstructured":"Serrano D, Bhowmick T, Chadha R, Garnacho C, Muro S. Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium. Arterioscler Thromb Vasc Biol. 2012;32:1178\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1374_CR79","doi-asserted-by":"crossref","unstructured":"Yu YJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.","DOI":"10.1126\/scitranslmed.3002230"},{"key":"1374_CR80","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/pharmaceutics15030864","volume":"15","author":"R Daniele","year":"2023","unstructured":"Daniele R, et al. Influence of Folate-Targeted Gold Nanoparticles on Subcellular Localization and Distribution into Lysosomes. Pharmaceutics. 2023;15:864.","journal-title":"Pharmaceutics"},{"key":"1374_CR81","first-page":"958","volume":"14","author":"V Prachayasittikul","year":"2015","unstructured":"Prachayasittikul V, Worachartcheewan A, Shoombuatong W, Prachayasittikul V, Nantasenamat C. Classification of p-glycoprotein-interacting compounds using machine learning methods. EXCLI J. 2015;14:958\u201370.","journal-title":"EXCLI J"},{"key":"1374_CR82","doi-asserted-by":"publisher","first-page":"C1339","DOI":"10.1152\/ajpcell.00099.2003","volume":"285","author":"S Muro","year":"2003","unstructured":"Muro S, et al. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Physiol. 2003;285:C1339\u201347.","journal-title":"Am J Physiol Physiol"},{"key":"1374_CR83","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1083\/jcb.201507112","volume":"212","author":"DE Johnson","year":"2016","unstructured":"Johnson DE, Ostrowski P, Jaumouill\u00e9 V, Grinstein S. The position of lysosomes within the cell determines their luminal pH. J Cell Biol. 2016;212:692.","journal-title":"J Cell Biol"},{"key":"1374_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly N, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211:233\u201344.","journal-title":"J Exp Med"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01374-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01374-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01374-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T23:04:27Z","timestamp":1699052667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01374-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01374-z","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"20 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human subjects. The human cell model used is a commercial cell line with no personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}